Wakamoto Pharmaceutical Co.,Ltd.
Wakamoto Pharmaceutical Co.,Ltd. Fundamental Analysis
Wakamoto Pharmaceutical Co.,Ltd. (4512.T) shows weak financial fundamentals with a PE ratio of 38.94, profit margin of 3.21%, and ROE of 2.56%. The company generates $9.3B in annual revenue with weak year-over-year growth of 0.66%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 35.5/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 4512.T's fundamental strength across five key dimensions:
Efficiency Score
Weak4512.T struggles to generate sufficient returns from assets.
Valuation Score
Moderate4512.T shows balanced valuation metrics.
Growth Score
Weak4512.T faces weak or negative growth trends.
Financial Health Score
Excellent4512.T maintains a strong and stable balance sheet.
Profitability Score
Weak4512.T struggles to sustain strong margins.
Key Financial Metrics
Is 4512.T Expensive or Cheap?
P/E Ratio
4512.T trades at 38.94 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, 4512.T's PEG of 0.12 indicates potential undervaluation.
Price to Book
The market values Wakamoto Pharmaceutical Co.,Ltd. at 0.96 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 16.42 times EBITDA. This signals the market has high growth expectations.
How Well Does 4512.T Make Money?
Net Profit Margin
For every $100 in sales, Wakamoto Pharmaceutical Co.,Ltd. keeps $3.21 as profit after all expenses.
Operating Margin
Core operations generate 0.77 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $2.56 in profit for every $100 of shareholder equity.
ROA
Wakamoto Pharmaceutical Co.,Ltd. generates $1.89 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Wakamoto Pharmaceutical Co.,Ltd. generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Wakamoto Pharmaceutical Co.,Ltd. generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
4512.T converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
38.94
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.12
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.96
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.25
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.008
vs 25 benchmark
Current Ratio
Current assets to current liabilities
4.003
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.03
vs 25 benchmark
ROA
Return on assets percentage
0.02
vs 25 benchmark
ROCE
Return on capital employed
0.005
vs 25 benchmark
How 4512.T Stacks Against Its Sector Peers
| Metric | 4512.T Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 38.94 | 28.25 | Worse (Expensive) |
| ROE | 2.56% | 780.00% | Weak |
| Net Margin | 3.21% | -20122.00% (disorted) | Weak |
| Debt/Equity | 0.01 | 0.30 | Strong (Low Leverage) |
| Current Ratio | 4.00 | 4.66 | Strong Liquidity |
| ROA | 1.89% | -14687.00% (disorted) | Weak |
4512.T outperforms its industry in 2 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Wakamoto Pharmaceutical Co.,Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-28.65%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
103.89%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
-282.08%
Industry Style: Defensive, Growth, Innovation
Declining